Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia

Latest News

Doctor speaking to a female patient with obesity | Image credit: Studio Romantic - stock.adobe.com

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

By Laura Joszt, MA

June 18th 2025

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.

Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com

Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

By Laura Joszt, MA

June 12th 2025

Gene sequencing | Image Credit: RFBSIP - stock.adobe.com

Quality Improvement Project Enhances AML Genomic Testing Efficiency

By Laura Joszt, MA

June 11th 2025

Multiracial group of serious young adults sitting | Image credit: Drobot Dean

ALL Disparities, Treatment Gaps: AYA Patients Face Unique Challenges

By Laura Joszt, MA

June 4th 2025

Stephen Strickland, MD, MSCI | Image credit: SCRI

Durability, Reduced Toxicity of CAR NK Therapy in AML May Aid Curative Treatment

By Stephen Strickland, MD, MSCI
Interview by Mary Caffrey

May 13th 2025

More News

Vibrant abstract image of the world | Image credit: Tasnim - stock.adobe.com

February 14th 2024

Geographic, Sociodemographic Factors Significantly Influence AML in Elderly Patients

Investigators analyzed global, national, and regional trends in acute myeloid leukemia (AML), which predominantly affects individuals aged 60 to 89 years.

Lonely sad girl hugging a soft teddy bear | Image credit: Pictures Paradise - stock.adobe.com

February 8th 2024

Research Indicates In Utero Origins of Acute Leukemia in Children

Circumstantial and direct evidence, including a review of twin and backtracking studies, demonstrate potential prenatal development of acute childhood leukemias.

Man holding AML word on wooden cube | Image Credit: Andrey-stock.adobe.com

January 31st 2024

In AML, Immunotherapy Shows Promise to Expand Treatment Toolbox

Jared Kaltwasser

Most of the research suggests combination therapies might be the best option for many patients who have acute myeloid leukemia (AML).

AML Acute Myeloid Leukemia | Image Credit: momius-stock.adobe.com

January 29th 2024

ELN Risk Category, MRD Status Predictive of Relapse in Patients With AML

Jared Kaltwasser

The study may help explain why some patients are more prone to relapse following a complete response to induction therapy, as indicated by measurable residual disease (MRD) status and 2017 European LeukemiaNet (ELN) criteria.

Blood cells flowing - Катерина Євтехова - stock.adobe.com

January 27th 2024

Increased Fatigue Associated With Greater Risk of Mortality Among Patients With AML, ALL, MDS

The findings suggest patient-reported outcomes—namely fatigue—may be helpful in identifying patients at a higher risk of death and other adverse outcomes but warrant further research.

ASH 2023: Coverage of ALL

January 20th 2024

ASH 2023: Coverage of ALL

Selected coverage of acute lymphoblastic leukemia (ALL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12 2023, San Diego, California.

Findings Suggest Utility of Specialized MRD Testing in Management of FLT3-ITD AML With Quizartinib

January 5th 2024

Findings Suggest Utility of Specialized MRD Testing in Management of FLT3-ITD AML With Quizartinib

Red Blood Cells - Design Cells stock.adobe.com

December 22nd 2023

alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden

Those with chronic graft-versus-host-disease who have received allogeneic hematopoietic stem cell transplant (alloHSCT) may experience enhanced graft-versus-leukemia effects, thus producing a lower relapse rate in acute myeloid leukemia.

Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com

December 8th 2023

Health Care Resource Use, Cost Burden Appear Substantial in R/R B-Cell ALL

Treatment with blinatumomab or inotuzumab ozogamicin particularly confers higher total costs for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Child laying in hospital bed | Image credit: wavebreak3 - stock.adobe.com.jpg

November 3rd 2023

High Disease Burden at Acute Leukemia Diagnosis More Common in Black Children, Study Finds

A study evaluating disparities among children with acute leukemia found that Black children are more likely to present with higher disease burden at diagnosis compared with non-Hispanic White children.

High LDH Levels Associated With Worse Survival in Newly Diagnosed AML

October 13th 2023

High LDH Levels Associated With Worse Survival in Newly Diagnosed AML

Elevated white blood cell counts also appear to correlate with shorter overall survival in patients receiving standard induction chemotherapy plus cytarabine for acute myeloid leukemia.

Blood cells | Image credit: flashmovie - stock.adobe.com

September 8th 2023

AML-Specific Early Mortality Risk Indices May Increase Accuracy of Care Quality Measurements

A study found acute myeloid leukemia (AML) salvage therapy was independently associated with early mortality compared with frontline therapy, suggesting that algorithms measuring quality of care should incorporate risk mortality indices that factor in disease characteristics and treatment status.

image of leukemia cell

August 29th 2023

Older Patients With AML Less Likely to Receive Genomic Testing, Study Finds

A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions